Bronchiectasis is a heterogeneous condition and may be encountered as a stand-alone pulmonary disease by primary care clinicians and specialists in pulmonary medicine. Bronchiectasis sometimes ...
Panelists discuss how future bronchiectasis research will focus on precision medicine, identify treatable traits, and expand networks of Centers of Excellence to provide advanced care and clinical ...
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (NYSE American:ELMD) today announced the results of an independent, outcome-based clinical study presented during the third annual World ...
(MENAFN- GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Bronchiectasis pipeline constitutes 15+ key companies continuously working towards developing 15+ ...
In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP-1) ...
In March 2025, The Lancet Respiratory Medicine published a phase 2 clinical study article on China's first DPP-1 inhibitor, HSK31858, led by Academician Nan-shan Zhong and Professor Wei-jie Guan from ...
The Bronchiectasis and NTM Association announced today that two abstracts using Bronchiectasis and NTM Research Registry data were presented at the European Respiratory Society Congress, held ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback